Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

JANSSEN - CILAG FARMACÊUTICA LDA

NIF 500189412
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €24,814,006 151 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €24,814,006 151 contracts
A2 · Late Publication €42,712,129,159 4,935 contracts
Contract published to BASE more than 10 days after the signing date
LOW €42,712,129,159 4,935 contracts
A5 · Threshold Splitting €22,743,051 177 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €22,743,051 177 contracts
A6 · Low Competition €91,915,793 97 contracts
Only one bidder participated in a competitive procedure
MEDIUM €91,915,793 97 contracts
A9 · Price Overrun €50,998 5 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €12,223 3 contracts
MEDIUM €38,775 2 contracts
A9 · Abnormal Price Reduction €49,772,190,889 1,586 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €49,772,190,889 1,586 contracts
B5 · Benford's Law Deviation €1,119,077,276 4 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €1,119,077,276 4 contracts
C3 · Missing Mandatory Fields €45,926,897 112 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €45,926,897 112 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

693
€6,293,597,958
51
€4,427,745,954
117
€2,755,649,371
512
€1,547,449,221
127
€1,465,498,131
70
€1,451,746,778
91
€1,404,595,235
225
€1,393,538,222
160
€1,387,505,100
264
€1,384,325,190
77
€1,371,811,757
42
€1,345,899,313
474
€1,321,027,153
359
€1,248,942,630
31
€1,247,538,126
44
€1,222,389,256
47
€1,218,900,423
46
€1,207,957,071
101
€1,152,390,544
216
€1,113,648,059
Page 1 of 4 · 70 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 142 · 7,070 contracts

BEAD20260042 - AQUISIÇÃO DE ANTÍVIRICOS-DARUNAVIR+COBICISTATE+EMTRICITABINA+TENOVOFIR ALAFENAMIDA
PT · 13730569 · Ao abrigo de acordo-qu...
€568,320 2026-02-27
ANTIANDROGENIOS - APALUTAMIDA
PT · 13730365 · Ao abrigo de acordo-qu...
€646,956 2026-02-27
261Y000176 - MEDICAMENTOS DO GRUPO 4: SANGUE
PT · 13718649 · Ao abrigo de acordo-qu...
€224,251 2026-02-27
IMUNOMODULADORES - GOLIMUMAB
PT · 13703949 · Ao abrigo de acordo-qu...
€424,057 2026-02-27
261Y000185/13559 - VÁRIOS MEDICAMENTOS
PT · 13673132 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€45,102 2026-02-26
261X000057 - TECLISTAMAB
PT · 13697955 · Contratação excluída II
€236,654 2026-02-25
261Y000183/28341-Aquisição Medicamentos ao abrigo A.Q. 2023/0491
PT · 13676465 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€157,489 2026-02-25
261Y000183/28341-Aquisição Medicamentos ao abrigo A.Q. 2023/0491
PT · 13676339 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€157,489 2026-02-25
2026/0126 - Convite à apresentação de proposta por ajuste direto para aquisição de AMIVANTAMAB [50 MG/ML; 7 ML; SOL INJ; FRS], BOSENTANO [32 MG; COMP DISP], BEDAQUILINA [100 MG; CÁP/COMP], DARUNAVIR [100 MG/ML; SUSP ORAL; FRS], TECLISTAMAB [90 MG/ML; 1,7 ML; SOL INJ; FRS] e TECLISTAMAB [10 MG/ML; 3 ML; SOL INJ; FRS]
PT · 13634306 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction
€1,602,358 2026-02-25
Aquisição de Medicamentos diversos (AQ2025/1627)
PT · 13587805 · Ao abrigo de acordo-qu...
€283,735 2026-02-23
BEAD20260124 - AQUISIÇÃO DE IMUNOMODULADORES - USTECINUMAB
PT · 13582187 · Ao abrigo de acordo-qu...
€335,475 2026-02-23
EXCL JANSSEN_ ERDAFITINIB 3MG
PT · 13609887 · Ajuste Direto Regime G...
€29,158 2026-02-21
Aquisição de USTECINUMAB ORIGINAL SC 90MG1ML INJ SER, ao Lab. J & J, para a ULSASI, para o ano de 2026
PT · 13544307 · Ajuste Direto Regime G...
€57,688 2026-02-20
Aquisição de Medicamentos do Aparelho Cardiovascular
PT · 13511841 · Ao abrigo de acordo-qu...
€1,113,303 2026-02-20
41/1205/2026 - Medicamentos antipsicóticos, anestésicos e relaxantes musculares
PT · 13677452 · Ao abrigo de acordo-qu...
€168,559 2026-02-19
261Y000146 - AQUISIÇÃO DE MEDICAMENTOS DIVERSOS - 1589/2025
PT · 13494352 · Ao abrigo de acordo-qu...
€181,839 2026-02-19
261Y000112 - DE MEDICAMENTOS DO FORO ONCOLÓGICO E IMUNOMODULADORES
PT · 13487713 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€445,429 2026-02-19
261Y000125/13559 - VÁRIOS MEDICAMENTOS
PT · 13479173 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€60,760 2026-02-19
Aquisição de Medicamentos Exclusivos Janssen Cilag - Paliperidona LP - 2026
PT · 13586189 · Ajuste Direto Regime G...
€94,893 2026-02-18
050101342026 TECLISTAMAB 10 MG/ML SOL INJ FR 3 ML SC - JUSTIFICAÇÃO CLINICA
PT · 13497626 · Ao abrigo de acordo-qu...
€3,280 2026-02-18
261X000036 - AMIVANTAMAB 350 MG INJ
PT · 13462998 · Contratação excluída II
€43,881 2026-02-18
Ajuste direto para aquisição de U41, U42, U43, U39 e U40
PT · 13588363 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction
€2,638,592 2026-02-16
IMUNOMODULADORES - GUSELCUMAB
PT · 13435459 · Ao abrigo de acordo-qu...
€329,840 2026-02-16
Aquisição de Vários Medicamentos antipsicóticos, anestésicos e relaxantes musculares CPA 1428/2025
PT · 13621862 · Ao abrigo de acordo-qu...
A2 · Late Publication
€175,299 2026-02-12
261Y000109/13559 - VÁRIOS MEDICAMENTOS
PT · 13320052 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€119,103 2026-02-12
PC 40260015 - Aquisição Guselcumab 100mg/1ml
PT · 13345032 · Ao abrigo de acordo-qu...
€0 2026-02-11
PC 40260014 - Aquisição de Golimumab 50Mg/0.5ML
PT · 13344262 · Ao abrigo de acordo-qu...
€0 2026-02-11
BEAD20260044 - AQUISIÇÃO DE ANTICOAGULANTES E ANTITROMBÓTICOS
PT · 13301682 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€434,048 2026-02-11
261Y000155 - AQUISIÇÃO DE MEDICAMENTOS DIVERSOS
PT · 13298834 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€10,484 2026-02-11
EXCLS SPMS (2024_0961)
PT · 13278387 · Ao abrigo de acordo-qu...
€2,568,659 2026-02-11
MEDICAMENTOS DIVERSOS AQ 2025/1428
PT · 13419856 · Ao abrigo de acordo-qu...
€140,560 2026-02-10
SELEXIPAG 1600 ¿G COMP
PT · 13530253 · Ajuste Direto Regime G...
A2 · Late Publication
€13,063 2026-02-09
Aquisição de Medicamentos do grupo 4: sangue - AQ2023/304
PT · 13454954 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€443,632 2026-02-09
SPMS (2025_1428) VARIOS
PT · 13373741 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€4,678 2026-02-09
Aquisição de Medicamentos Exclusivos Janssen Cilag - Bedaquilina - 2026
PT · 13221245 · Ajuste Direto Regime G...
€235,272 2026-02-09
261Y000078/13559 - VÁRIOS MEDICAMENTOS
PT · 13202531 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€860,598 2026-02-09
ISONIAZIDA 50 MG + PIRAZINAMIDA 300 MG + RIFAMPICINA 120 MG COMP
PT · 13529509 · Ajuste Direto Regime G...
A2 · Late Publication
€1,817 2026-02-06
J1/227/2026 – ESCETAMINA 28 MG SOL P/A PULV NASAL FRS 0,2 ML
PT · 13433151 · Ajuste Direto Regime G...
€451,925 2026-02-06
ANTIPSICOTICOS - RISPERIDONA E PALIPERIDONA
PT · 13179056 · Ao abrigo de acordo-qu...
€488,511 2026-02-06
40260012 - Aquisição de Medicamentos Antipsicóticos
PT · 13180130 · Ao abrigo de acordo-qu...
€0 2026-02-04
Q1/231/2026 - AGREGAÇÃO URGENTE - DARATUMUMAB 120 MG/ML SOL INJ FR 15 ML SC
PT · 13448883 · Ao abrigo de acordo-qu...
A2 · Late Publication
€499,942 2026-02-03
Aquisição de Medicamentos antipsicóticos, anestésicos e relaxantes musculares AQ1428/2025
PT · 13267808 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction
€2,329,696 2026-02-03
261Y000064/13559 - VÁRIOS MEDICAMENTOS
PT · 13125241 · Ao abrigo de acordo-qu...
€4,464,905 2026-02-03
2025009256/HFAR-Aquisição de medicamentos
PT · 13125236 · Ajuste Direto Regime G...
€9,242 2026-02-03
ANTIPSICOTICOS - PALIPERIDONA
PT · 13108625 · Ao abrigo de acordo-qu...
€467,946 2026-02-03
COMPRAS URGENTES
PT · 13136942 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction
€150,633 2026-01-30
SP 652-2026 Aquisição de Golimumab 50 mg/0.5 ml Sol inj Caneta 0.5 ml SC, para a ULSTMAD, EPE (AQ 2025/1589)
PT · 13655598 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,761 2026-01-28
Aquisição do Medicamento Paliperidona 525 mg Susp inj LP Ser 2.625 ml IM
PT · 13585742 · Ajuste Direto Regime G...
A2 · Late Publication
€4,679 2026-01-28
ANTIVIRICOS - DARUNAVIR + COBICISTATE, ETRAVIRINA E RILPIVIRINA
PT · 12947201 · Ao abrigo de acordo-qu...
€99,460 2026-01-28
EXCL JANSSEN - APALUTAMIDA 240 MG - URGENTE
PT · 12901638 · Ajuste Direto Regime G...
€194,296 2026-01-27
Next →
Overview
Total Value Won
€50,579,567,987
Contracts Won
7,070
Score 231630 · CRITICAL RISK
NIF
500189412
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

No director data imported yet.

Director and fiscal identity data for Portuguese companies can be found in the Registo Comercial (publicacoes.mj.pt).

Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned